Answers are grounded in this paper and cite their sources.
Observational study identifies factors associated with high healthcare utilisation in metabolic dysfunction-associated steatotic liver disease, highlighting unmet medical needs.
Despite its high prevalence in the western world metabolic dysfunction-associated steatotic liver disease (MASLD) does not benefit from targeted pharmacological therapy. We measured healthcare utilisation and identified factors associated with high-cost MASLD patients in France.
No takes yet. Share an insight, caveat, or question.
Ossima et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: